April 11th
Greetings Readers,
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) could start earning some serious breakout buzz.
Why? How about a fresh green surge that took place after Thursday's closing bell on the heels of dropping breaking news?
Check it out:
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
GAITHERSBURG, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), ..., today announced the filing of a key provisional patent application with the United States Patent and Trademark Office (USPTO) entitled "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy."
The filing is yet another critical advancement within the Company's Diagnostic subsidiary which aims to develop highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, leveraging its high expression on prostate cancer cells for accurate imaging and for targeted therapy delivery using radio labelled PSMA ligands.
...
"I believe a significant opp. exists for PSMA ligands for prostate cancer diagnosis and treatment," commented Anatoly Dritschilo, MD, Shuttle Pharma's Chairman and Chief Scientific Officer. "The Shuttle Pharma scientists have collaborated with Dr. Kozikowski on discovery projects for radiation sensitizing drugs and have recently focused on discovery of novel PSMA ligands with the intent of targeting prostate cancer cells preferentially to the effects of radiation and chemotherapeutic agents. We look forward to the continued advancement of our Shuttle Diagnostics' subsidiary and the opp. to develop a theranostic that has the potential to play a significant role in the future diagnosis and treatment of prostate cancer."
...
Read the full article here.
Take a moment to review my initial report below and consider this low float (fewer than 4Mn shares) Nasdaq profile (SHPH) for your radar Friday.
-----
Well... That was something.
While the overall markets haven't been able to figure out what to do, my profile for Wednesday absolutely wore its chart out.
Brought into focus Tuesday night following an after-hours close of $1.07, this most recent breakout idea ripped before the bell to a high of $5.64.
In a stunning set of events, that Nasdaq profile turned heads with a move of approx. 427%!
After spinning my head back on to my neck, I sought to move forward putting together a new report on a new breakout idea.
Similarly enough, just like this most recent alert, this profile trades on the Nasdaq and has a low float.
Though this profile shares these similarities and more with Wednesday's profile that surged an approx. 427%, these characteristics alone aren't any indication that this next profile will undergo the same type of move.
But I will tell you this...
With significant news announcements in early 2025, this Nasdaq profile may not fly under Wall Street's radar for too much longer.
That's why you should consider turning your attention to:
*Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)*
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT).
And based on several potential catalysts, (Nasdaq: SHPH) tops my immediate watchlist. Take a look at them:
No. 1 - Could This Low Float Create A Scenario For Strong Volatility Potential?
No. 2 - Key Milestone Achieved As Phase 2 Clinical Trial Marches Forward.
No. 3 - Shuttle Announces Sponsored Research Agreement With UCSF To Advance PSMA Development Program.
No. 4 - Shuttle Announces Appointment Of Experienced Businessman, Christopher Cooper, As Co-CEO.
No. 5 - Shuttle Creates Added Flexibility To Advance Phase 2 Clinical Trial.
Pursuing a Cure for Cancer - Shuttle Pharmaceuticals Company Overview
Shuttle Pharmaceuticals is developing novel therapies designed to increase cancer cure rates, prolong patient survival, and improve quality of life.
Improving Outcomes for Cancer Patients
Shuttle Pharmaceuticals develops innovative therapies designed to target cancer cells, protect healthy tissue, and harness the body's innate immune response. Its mission is to enhance the efficacy of radiation therapy (RT) while minimizing side effects. By leveraging drug discovery and proprietary diagnostic technologies, the company aims to increase cancer cure rates and improve quality of life when its therapies are combined with radiation treatment.
The Next Revolution in Radiation Therapy
Radiation therapy is an effective and proven treatment modality for curing cancers. More than half of all patients diagnosed with cancer in the U.S. receive radiation therapy during their disease course.
Shuttle Pharmaceuticals is developing drugs to sensitize growing cancer cells, making them more susceptible to radiation, activating the DNA damage response pathway to kill malignant cells, and protecting adjacent healthy tissue. Its lead candidate, Ropidoxuridine, is an orally available halogenated pyrimidine with strong radiation-sensitizing properties.
Developing a Novel Portfolio
Using its platform technology to discover novel small molecules that modify the effects of ionizing radiation on cancer cells, Shuttle Pharmaceuticals has built a portfolio of patented selective histone deacetylase (HDAC) inhibitors. Strategic collaborations with academic research institutions have enabled the discovery and exclusive licensing of diagnostic technologies for prostate cancer patient management.
The company's pipeline includes a Phase II clinical-stage lead product (Ropidoxuridine), three preclinical HDAC inhibitors, and a diagnostic blood test under development for prostate cancer patients.
New Horizons in Diagnostic Technology
Prostate cancers vary in aggressiveness and treatment responses. Shuttle Pharmaceuticals' predictive biomarker strategy focuses on developing a diagnostic test to assess treatment success risk, guide therapeutic decisions, and inform follow-up management for prostate cancer patients considering elective radiation therapy.
Ropidoxuridine
Ropidoxuridine (IPdR) is Shuttle Pharmaceuticals' lead radiation sensitizer, designed for use with radiation therapy (RT) to treat glioblastoma, a deadly brain malignancy with no known cure. The FDA has granted the drug Orphan Designation, providing potential marketing exclusivity upon approval.
The oral halogenated pyrimidine incorporates into the DNA of rapidly growing cancer cells, increasing their sensitivity to radiation. Metabolites of IPdR generate reactive uracil free radicals, causing lethal DNA double-strand breaks upon radiation exposure.
Addressing a Critical Need
An estimated 800,000 U.S. patients receive radiation therapy annually, with about 50% undergoing treatment with curative intent. The market opp. for radiation sensitizers includes over 400,000 patients seeking cancer cures each year.
Shuttle Pharmaceuticals is conducting a Phase II trial of Ropidoxuridine for glioblastoma. Results may advance radiation sensitizers to improve cure rates, prolong survival, and enhance quality of life for patients.
HDAC Inhibitors
HDAC inhibitors regulate gene expression by modifying histones and non-histone proteins. Increased HDAC activity condenses chromatin, suppressing tumor suppressor genes, while inhibition opens chromatin, restoring their function. This epigenetic mechanism is a key focus in cancer research.
Driving Next-Gen Cancer Therapy
Shuttle Pharmaceuticals' R&D focuses on dual-functional molecules that sensitize tumors to radiation, protect healthy tissue, and activate immune responses against irradiated cancer cells. The company holds over 20 HDAC inhibitor patents across the U.S., Canada, and Europe.
Expanding Precision Oncology
Three lead candidates are in development for solid tumors:
- SP-2-225: A Class II (HDAC6)-selective inhibitor enhancing antigen presentation.
- SP-1-303: A Class I inhibitor targeting ER-positive cancers.
- SP-1-161: An ATM gene activator with applications in radiobiology.
Therapeutics Pipeline
